Balancing Near Term ROI and Foundational AI Innovation
The panel examined whether an open‑source business model can thrive in pharma, weighing short‑term ROI against the need for foundational AI research. Participants debated contributions from insurers and employers, likening the model to IBM’s investment in Linux. Speakers highlighted that tools such as OpenFold and Boltz already deliver commercial value, creating healthy competition with proprietary solutions. However, deeper innovations—like the early‑stage drug‑discovery platforms discussed—remain too distant from immediate payoff, requiring upfront capital despite uncertain returns. A recurring theme was the surprise that Google, not a biotech firm, built a key AI tool, underscoring pharma’s missed opportunity. The discussion referenced AlphaFold 2’s evolution into AlphaFold 3 and RF Diffusion, illustrating how early breakthroughs can cascade into transformative applications. The consensus calls for mechanisms to surface nascent problems, rally industry attention, and fund pre‑payoff projects. Bridging this gap could accelerate AI‑driven drug discovery and generate long‑term competitive advantage for pharma companies.
AI-Powered Autonomous Labs Underrated?
The discussion centered on a recent poll asking which AI trend will most transform drug discovery in the next three to five years. Multimodal models that integrate sequencing, molecular structure, and chemistry data captured the largest share at 41%, while...
How Federated Learning Could Bridge Pharma’s Data Divide
The video examines how federated learning can close the data gap that separates pharmaceutical companies from public chemical repositories. Each firm’s historical medicinal‑chemistry records are unique, and the industry lacks negative toxicology and bioactivity data, making local predictive models unreliable...
Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
The interview with Dr. Sarfaraz Niazi, CEO of RNA Therapeutics, explores his decades‑long journey from academia to industry and his pivotal role in shaping the biosimilar landscape. He recounts early work on biological drugs before the FDA had a formal...
Inside the Phased, Risk-Based Approach for CGT Materials
The video focuses on Bio4’s phased, risk‑based strategy for addressing particulate contamination in cell and gene therapy (CGT) raw and starting materials, a gap that has long plagued the industry. Bio4 is assembling a subgroup to draft best‑practice guidance, potentially...
Investing In Early-Stage Oncology With Yosemite's Dan McHugh
The Business of Biotech episode spotlights Dan McHugh, head of the investment team at Yosemite, a San Francisco‑based venture firm founded by Reed Jobs and Loren Powell Jobs. Yosemite’s mandate is to fund early‑stage cancer‑therapeutics developers, leveraging a mission‑driven capital pool that grew out of...
Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
In a Business of Biotech interview, Legend Biotech’s President Alan Bash discusses the commercial trajectory of Carvykti, the J&J‑partnered CAR‑T therapy for multiple myeloma that received FDA approval in 2022 and now generates blockbuster revenues. Bash highlights the product’s Q4 2025...
Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
In a recent Life Science Leader interview, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, outlined the company’s strategic shift toward radiotherapeutics targeting central nervous system (CNS) malignancies. The discussion centered on the lead asset, Rayobic, a Re‑186 beta‑emitting...
Navigating Private Equity Ownership in the CDMO Space
The Outsourced Pharma Live segment dissected how pharmaceutical companies can evaluate a CDMO’s financial resilience when owned by private‑equity firms. Panelists Jana Spes and Christine Sheaffer outlined precise questions to uncover sponsors’ reinvestment intentions and to confirm that leadership remains...
The BioSecure Act & Unfiltered Supply Chain Realities
The Outsourced Pharma Live panel highlighted the urgent need for supplier‑level visibility of raw materials and packaging as geopolitical tensions threaten supply continuity. Speakers emphasized that transferring technology to established U.S. CDMOs is a capital‑intensive, time‑consuming process. Jana Spes and...
The "Bad News" Stress Test: How CDMOs Handle Escalation
The Outsourced Pharma Live segment highlighted a "bad news" stress test for evaluating CDMOs during due diligence. Panelists Jana Spes and Christine Sheaffer explained how to map escalation pathways by pinpointing key decision‑makers and probing the partner’s problem‑solving culture. They...
What Great CDMO Selection Looks Like In 2026
The Outsourced Pharma Live panel redefines what makes a great CDMO in 2026, shifting focus from raw capacity and technical capability to how partners execute under uncertainty. Christine Sheaffer emphasizes the importance of managing change without triggering contract disruptions, delivering...
The One Quality Metric That Actually Matters
During the Outsourced Pharma Live event, panelists Jana Spes and Christine Sheaffer highlighted three internal quality metrics that cut through marketing hype to reveal a CDMO’s true quality culture. They emphasized deviation closure times, batch record cycle times, and CAPA...
AI Meets Cell Therapy Manufacturing
Senti Biosciences executives Tim Lu and Claire Aldridge told Cell & Gene Live that artificial intelligence is reshaping cell‑therapy manufacturing by speeding up, not replacing, wet‑lab steps. They highlighted robust validation data that demonstrates AI‑driven processes are reliable. The speakers...
Unlocking AI's Potential in Cell Therapy Through Robust Data
In the closing session of Cell & Gene Live, Senti Biosciences executives Tim Lu and Claire Aldridge argued that a high‑quality, diverse data infrastructure is the cornerstone for applying AI and synthetic biology to cell and gene therapies. They stressed...
